Aptar’s Nasal Delivery System Enters Phase II Trial with ENA Respiratory
Event summary
- Aptar’s Unidose Powder Nasal Delivery System is being used in ENA Respiratory’s Phase II clinical trial for INNA-051, an investigational nasal spray targeting symptomatic viral respiratory infections.
- The trial, which began dosing participants in March 2026, aims to assess the safety, tolerability, and effectiveness of INNA-051 in adults at high risk of viral exposure.
- Aptar’s system features a single-dose, precise powder delivery mechanism with moisture protection via Activ-Polymer™ technology.
- ENA Respiratory’s INNA-051 is designed as a once-weekly nasal spray to reduce the burden of symptomatic respiratory viral illness.
The big picture
Aptar’s involvement in ENA Respiratory’s Phase II trial underscores the rising demand for non-vaccine solutions in respiratory health. The collaboration highlights the strategic importance of intranasal delivery systems in developing novel therapies, particularly as the industry shifts toward virus-agnostic treatments. Aptar’s technology could play a key role in advancing such innovations, provided the trial yields positive results.
What we're watching
- Trial Success
- Whether INNA-051 demonstrates sufficient safety and efficacy in Phase II to advance to later-stage trials.
- Market Adoption
- The pace at which Aptar’s nasal delivery system gains traction in other clinical and commercial applications.
- Competitive Positioning
- How Aptar’s technology differentiates itself in the growing market for intranasal drug delivery solutions.
Related topics